Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that alopecia is a common but often underreported side effect of endocrine-based cancer therapies, with tamoxifen showing the highest incidence of hair loss among analyzed treatments.

This review discusses the cardiovascular risks associated with anabolic-androgenic steroid use and reports that, despite known toxic effects, further research is needed to clarify the causality of these risks.

This study found that some synthesized heterocyclic derivatives showed promising 5α-reductase inhibitor, antiviral, and anti-tumor activities, surpassing several reference drugs in effectiveness.

This study found that testosterone enhances insulin secretion in human pancreatic islets by being converted into DHT and E2, processes that are necessary for this effect.

This abstract provided no research findings as it contains only website navigation and service information.

This review suggests that treating endocrine therapy-induced hair loss in breast cancer patients with topical 5-alpha reductase inhibitors and supplements like Vitamin C and omega-3 fatty acids may be effective, but further studies are needed.

This review discusses the efficacy and safety of exemestane as a treatment for estrogen-receptor-positive breast cancer and reports no new clinical results.

This case study reports that a woman with breast cancer experienced persistent alopecia after taxane chemotherapy and endocrine therapy, and significant improvement was seen with topical minoxidil.

This article provides a reference guide for various dermatological terms, treatments, and conditions, but reports no new clinical findings.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

There is no significant link between insulin resistance and certain hair disorders like idiopathic hirsutism and androgenic alopecia.

Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.

This study found that a significant portion of counterfeit drugs seized among bodybuilders did not match their labels, with many containing undeclared anabolic steroids or other unexpected active ingredients.

PFS affects some women, steroids easily bought online, hypogonadism info unreliable, low testosterone linked to CVD.

This study found that 4-MA is a potent inhibitor of testosterone 5α-reductase in human tissues, promising potential for treating androgen-dependent skin conditions like male pattern baldness.

The researchers reported that compounds 11 to 13 derived from Westphalen-type steroids showed strong antiandrogenic activity in vivo, though their effects could not be attributed to 5α-reductase inhibition or androgen receptor binding.

This narrative review attributes antiandrogenic properties to spironolactone, reporting its effectiveness in treating dermatological conditions like alopecia androgenica, acne, and hirsutism, though highlighting necessary attention to potential adverse effects and contraindications.

This study found that letrozole, an aromatase inhibitor, reduced the incidence and severity of PTZ-induced kindling seizures in mice, potentially due to its effects on 17β-estradiol and neurosteroid synthesis.

This study identified novel 4-Amino-2H-benzo[h]chromen-2-one analogs as potent androgen receptor antagonists that show strong antiproliferative activity against prostate cancer cells, suggesting them as potential lead compounds for therapy development.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

This case report suggests that spironolactone may induce prostate cancer proliferation in patients on abiraterone acetate, advising against its use for managing treatment-associated side effects in these individuals.

This study investigated various synthesized 5-reductase inhibitors and found that compound 6 had the highest anti-androgenic activity and receptor affinity compared to finasteride, showing potential due to its improved efficacy and bioavailability for further research in treating lower urinary tract symptoms.

This study reports the discovery of LX-38, a new high-affinity non-steroidal antagonist that could provide the therapeutic benefits of current BPH and AGA treatments without the hormonal side effects, utilizing a distinct "Orthogonal T-Stacking" scaffold for binding.

This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.

This review discusses the role of androgens in the progression of cardiovascular disease and explores novel therapeutic targets without reporting new clinical results.

This review discusses the role of DHEA in intracrinology, highlighting its impact on breast and prostate cancer treatment and potential as a menopause therapy, but reports no new research findings.

This study suggests that increased use of anticancer drugs from 2004 to 2008 has led to higher environmental release, necessitating expanded monitoring and research on their ecotoxicological impacts.